Translating cancer biology into medicines October 2020 Disclaimer This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend on ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance & Chief Operating Officer Judy Chiao - Vice President of Clinical Development & Regulatory Affairs Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Kumar Raja - Brooklyn Capital Markets Wangzhi Li - Ladenburg Operator Good after ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2020 Results Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Jonathan Aschoff - Roth Capital Partners Wangzhi Li - Ladenburg Kumar Raja - Brooklyn Capital Markets Operator G ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2019 Results Conference Call February 26, 2020 4:30 PM ET Company Participants Jan Medina - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Dr. Judy Chiao - Vice President of Clinical Development and Regulatory Affairs Conference Call Participants Wangzhi Li - Ladenburg Thalmann Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Fourth Quar ...

Translating cancer biology into medicines NASDAQ CYCC – BIOCEO Conference February 10, 2020 Disclaimer | --- | --- | |-------------------------------------------------------------------------------------|---------------| | | | | This presentation contains forward-looking statements | within the | | meaning of the "safe harbor" provisions of the Private Securities | Litigation | | Reform Act of 1995 about financial results and estimates, | business | | strategy, clinical trial plans and research and developm ...

Translating cancer biology into medicines NASDAQ CYCC Biotech Showcase - January 13, 2020 Disclaimer | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------| | | | | This presentation contains forward-looking statements within | the meaning | | of the "safe harbor" provisions of the Private Securities | Litigation Reform | | Act of 1995 about financi ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2019 Earnings Conference Call November 13, 2019 4:30 PM ET Company Participants Jan Medina – Russo Partners LLC Spiro Rombotis – President and Chief Executive Officer Paul McBarron – Executive Vice President-Finance and Chief Operating Officer Judy Chiao – Vice President-Clinical Development and Regulatory Affairs Conference Call Participants Wangzhi Li – Ladenburg Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2019 Results ...

CYC 682 Translating cancer biology into medicines NASDAQ CYCC September 2019 Disclaimer | --- | --- | |--------------------------------------------------------------------------------------|---------------| | | | | This presentation contains forward-looking statements | within the | | meaning of the "safe harbor" provisions of the Private | Securities | | Litigation Reform Act of 1995 about financial results and | estimates, | | business strategy, clinical trial plans and research and | development | | prog ...

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2019 Results Earnings Conference Call August 13, 2019 4:30 PM ET Company Participants Paul McBarron - Executive VP of Finance, CFO, COO, Secretary & Executive Director Spiro Rombotis - President, CEO & Executive Director Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2019 Results Conference Call and Webcast. (Operator Instructions) The company will al ...

Start Time: 16:30 January 1, 0000 4:50 PM ET Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q1 2019 Earnings Conference Call May 14, 2019, 16:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO and Secretary Judy Chiao - VP, Clinical Development and Regulatory Affairs Alexander Fudukidis - IR, Russo Partners LLC Conference Call Participants Wangzhi Li - Ladenburg Thalmann & Co. Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter ...